Startup | May 09, 2022
InxMed raises US $ 15 million in Series B+ financing
The plan is to advance innovative therapies to drug-resistant cancers
The plan is to advance innovative therapies to drug-resistant cancers
Ahead of International Thalassemia Day on 8th May, medical professionals and representatives of patient bodies participated in a virtual discussion on the current situation of Thalassemia management in India
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
With the introduction of this device, Alkem is entering the core inhalation therapeutics and envisaging that the drug will reach the lungs effectively in each inhalation with added patient awareness and adherence programmes
At an affordable price, a researcher can process fresh samples of 10,000 cells immediately with a stable stopping point within two hours, simplifying sample management at the laboratory and limiting transcriptional changes
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
The procedures have been performed by Dr. Kaushal Pandey at P.D. Hinduja Hospital in Mumbai, India
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
It affects up to 10 per cent of women of reproductive age around the world
Subscribe To Our Newsletter & Stay Updated
